Rubicon Research Limited was incorporated on May 6, 1999, as a Private Company as Rubicon Consultants Private Limited', with the RoC. Subsequently, the Company's name was changed from Rubicon Consultants Private Limited' to Rubicon Research Private Limited' to which a fresh Certificate of Incorporation was issued by the RoC dated September 2, 2002. The Company's status got converted from a Private Company to a Public Company, the name was changed from Rubicon Research Private Limited' to Rubicon Research Limited'. A fresh Certificate of Incorporation dated July 23, 2024 was issued by the Central Processing Centre, Manesar, Haryana.
Rubicon Research is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development and production of pharmaceutical products. The Company is driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets, particularly, the United States. It has obtained its GMP manufacturing facilities at Ambernath and Satara in Maharashtra.
The Company commenced manufacturing of certain special drugs in Ambernath Manufacturing Facility in 2011. In 2016, the Company acquired majority stake by ECP III Pte Ltd. Further, it acquired majority stake by General Atlantic Singapore RR Pte. Ltd., from ECP III Pte. Ltd. in 2019. In 2021, the Company acquired the business of Meditab Specialities Limite ...d on slump sale as a going concern.
In FY 2024, the Company acquired Validus, a New Jersey headquartered marketer of brand name formulation products in the US. It commenced the manufacturing of nasal products at Ambernath Plant in 2024. The Company has acquired Pithampur Manufacturing Facility from Alkem Laboratories Ltd in 2025.
The Company came up with its initial public offering of 28,405,841 equity shares of face value of Re 1 each, by raising funds aggregating to Rs 1378 crores, comprising a fresh issue of 10,313,058 equity shares aggregating to Rs 500 crores and the offer for sale of 18,092,783 equity shares aggregating to Rs 878 crores on October 13, 2025.
The Company acquired 85% stake in Arinna Lifesciences Limited at Pithampur in April 2026.
FAQs on Rubicon Research Ltd
1. Can I buy Rubicon Research Ltd from PL Capital? ›
Yes, you can invest in Rubicon Research Ltd shares directly through PL Capital. Our platform provides a seamless and secure way to buy, hold, and track Rubicon Research Ltd stock along with other leading companies listed on the NSE and BSE. Simply open a Demat and trading account with PL Capital, and you’ll be able to trade Rubicon Research Ltd as well as diversify your portfolio across equities, mutual funds, IPOs, and more.
2. Does Rubicon Research Ltd pay dividends? ›
Yes, Rubicon Research Ltd has a consistent history of rewarding its shareholders through dividend payouts. Dividend frequency and amounts vary depending on the company’s financial performance and board approvals. Investors holding Rubicon Research Ltd shares on the record date announced by the company are eligible to receive dividends directly into their bank accounts linked with their Demat holdings.
3. What is the current share price of Rubicon Research Ltd ? ›
As of
11-Aug-2026 , 15:57:14 the share price for Rubicon Research Ltd. is ₹ 1655.1 on the NSE (Note: Prices are dynamic and update frequently during market hours).
4. What is the 52-week high and low of Rubicon Research Ltd ? ›
The 52-week high and low of Rubicon Research Ltd share price is ₹ 570.75 - ₹ 1684.1 as of
11-Aug-2026 , 15:57:14 .
Open Your Demat Account with PL Capital now
10 Lakh+ Active users
Award Winning research insights
No hidden charges
Start Stock SIP
Start SIP in Rubicon Research Ltd
Invest systematically in stocks with the PL Capital app
